Division of Pharming Group NV
Latest From Pharming NV
Emerging Company Profile: With a Phase I clinical trial starting in Q3 and Series A funding to raise, HOX Therapeutics is taking a step out of the shadows of academia to develop its novel drug candidates in brain and prostate cancer. CEO Karl Keegan spoke to Scrip about what is next for the UK company.
Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.
CSL Behring’s long-acting subcutaneous C1 inhibitor formulation, CSL830, has confirmed its efficacy for the prevention of hereditary angioedema (HAE) attacks, and is expected to be introduced this year, giving it initial traction in what could become a crowded sector.
Pipeline Watch has been updated to bring greater depth and detail to a potential therapeutic product’s progress through the R&D pipeline. The table brings you a snapshot of selected late-stage clinical trial events in the pharma and biotech industries.
All set! This article has been sent to email@example.com.
All fields are required. For multiple recipients, separate email addresses with a semicolon.